Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paroxetine + duloxetine
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a comparative clinical study (NCT00311402) conducted by Duke University to evaluate the effects of paroxetine controlled release (CR) versus duloxetine on heart rate variability (HRV) and autonomic cardiovascular control in patients with major depressive disorder (MDD). Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that works by inhibiting the serotonin transporter (SERT), thereby increasing serotonin levels in the synaptic cleft. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that inhibits both the serotonin transporter (SERT) and the norepinephrine transporter (NET). The trial aimed to compare the safety profiles of these two classes of antidepressants regarding their impact on the autonomic nervous system, which is often dysregulated in depressed patients and can contribute to cardiovascular risk.
- Brand names
- PaxilCymbaltaPexevaIrenka
- Other names
- paroxetine versus duloxetine-Duke University-major depressive disorderparoxetine vs. duloxetine
02
Targets
CYP2D6 (Cytochrome P450 2D6)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on paroxetine + duloxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paroxetine + duloxetine.